Anavex Life Sciences

Anavex Life Sciences Corp. is a biopharmaceutical company that utilizes its patented drug discovery SIGMACEPTOR™ platform to focus on the discovery and development of novel therapeutics for neurological disorders and cancer. The company's Alzheimer's disease (AD) candidate drug, ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. Anavex leverages precision genetic medicine to treat severe and debilitating neurological conditions, aiming to serve patients with rare diseases (Rett syndrome) and high-risk CNS populations (Parkinson’s disease, Alzheimer’s disease).